Teva stock falls 1.22 percent as Oppenheimer sets USD 50.00 target

Published on 09/28/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock stood at USD 38.71 on September 28, 2026, with a USD 45.1 billion market capitalization. Q2 revenue reached USD 4.14 billion.

TEVA, US88162G1031, Illustration mit AI erstellt.

Teva Pharmaceutical Industries stock (ISIN US88162G1031) was trading at USD 38.71 on the NYSE on September 28, 2026, down 1.22 percent from the previous close of USD 39.19. The latest analyst catalyst came on September 23, when Oppenheimer began coverage with an outperform rating and a USD 50.00 price target, according to MarketBeat.

Oppenheimer sets USD 50.00 target

The target stands 29.14 percent above the September 28 intraday price. MarketBeat reported that Oppenheimer set the USD 50.00 target alongside an outperform rating, while 11 analysts carried Buy ratings and one analyst held a Hold view, producing a USD 43.73 average target.

Q2 revenue reaches USD 4.14 billion

Teva's second-quarter picture was mixed. A summary of the company's Q2 2026 filing by StockTitan put net revenue at USD 4.14 billion, down 1 percent year over year. GAAP net loss was USD 576.0 million, or USD 0.49 per diluted share, while non-GAAP diluted EPS was USD 0.02. The loss included USD 724.0 million of acquired in-process research and development expenses.

The same Q2 filing summary said AUSTEDO, AJOVY and UZEDY generated more than USD 1.0 billion together and grew 43 percent in local currency. That contrast gives the current valuation debate two separate reference points: expanding innovative brands and a costly acquisition-related charge.

NYSE listing broadens access

Teva began direct trading of its ordinary shares on the NYSE on September 14, 2026, ending its American Depositary Shares program while retaining the TEVA ticker, according to Teva. The company continues to trade under TEVA on the Tel Aviv Stock Exchange.

Teva stock remains below its yearly high

At USD 38.71 on September 28, 2026, Teva stock was 5.10 percent below its 52-week high of USD 40.79 and above its 52-week low of USD 18.47. Trading volume stood at 679,362 shares, while market capitalization was USD 45.1 billion.